SOPHiA GENETICS SA
Close on Oct 19, 2026
- Market cap
- $479.21M
- P/E (TTM)
- –
- Dividend yield
- –
About SOPHiA GENETICS
Services-Computer Processing & Data Preparation, SIC 7374
SOPHiA GENETICS is a healthcare software company that develops a cloud-based analytics platform for data-driven medicine. Its core product, SOPHiA DDM, standardizes and analyzes complex genomic and multimodal health data for applications across oncology, rare diseases, cardiology, and neurology. The company also offers the Alamut interpretation software, the SOPHiA CarePath multimodal module, and biopharma solutions for clinical trials and companion diagnostics. Its customers include academic and community hospitals, reference and specialty laboratories, and biopharmaceutical firms.
Headquartered in Rolle, Switzerland, the company operates across 75 countries through a direct commercial presence in 60 countries and distributors in 50 countries. It serves more than 993 hospital, laboratory, and biopharmaceutical customers globally and has supported the analysis of approximately 2.3 million genomic profiles. The company maintains nine regional data centers located in Switzerland, France, the Netherlands, the United States, Canada, Brazil, Australia, and the United Arab Emirates.
Summary of the business section of SOPHiA GENETICS's latest annual report, written by StockData.
Company profile
Company
- Legal name
- SOPHiA GENETICS SA
- Founded
- 2011
- Headquarters
- Rolle, V8
- Address
- La Piece, Ch-1180 00000
- Phone
- 41 21 694 10 60
- Website
- sophiagenetics.com
- Employees
- 415, Dec 31, 2025
- Industry
- Services-Computer Processing & Data Preparation
- Incorporated in
- V8
- Fiscal year ends
- December 31
- Auditor
- PricewaterhouseCoopers SA, Lausanne, Switzerland
Stock & identifiers
- Ticker
- SOPH
- Exchange
- Nasdaq
- IPO date
- Jul 23, 2021
- Shares outstanding
- 68M, Dec 31, 2025
- Filer category
- Accelerated filer<br>Emerging growth company
- SEC CIK
- 1840706
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Ross Muken | Chief Executive Officer, Director | 870,229 |
| Jurgi Camblong | Executive Chairman, Director | 3,435,822 |
| George Cardoza | Chief Financial Officer | 308,318 |
| Zhenyu Xu | Chief Scientific Officer | 552,887 |
| Philippe Menu | Chief Medical Officer | 208,387 |
| Well Daan Van | Chief Legal Officer | 338,884 |
| Abhimanyu Verma | Chief Technology Officer | 172,171 |
| Manuela Valente | Chief People Officer | 220,450 |
| Kevin Puylaert | Chief Sales Officer | 147,948 |
| Kathy L. Hibbs | Director | 96,992 |
| Troy Cox | Director | 328,743 |
| Didier Hirsch | Director | 240,220 |
| Vincent Ossipow | Director | 522,860 |
| Jean-Michel Cossery | Director | 206,212 |
| Tomer Berkovitz | Director | – |
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 415 full-time equivalents (“FTE”) across 28 countries, of whom 308 were located in EMEA, 80 were located in North America, 14 were located in Latin America and 13 were located in Asia Pacific.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Jul 23, 2021 | IPO | Initial public offering priced (424B4 prospectus) |
| Jul 19, 2021 | Listing | Registration of securities on an exchange (Form 8-A) |